Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study

被引：0
|
作者：
Ambrose, Chris [1 ]
Colice, Gene [1 ]
Salapa, Kinga [2 ]
Parnes, Jane [3 ]
Corren, Jonathan [4 ]
机构：
[1] AstraZeneca, Gaithersburg, MD USA
[2] AstraZeneca, Warsaw, Poland
[3] Amgen Inc, Thousand Oaks, CA USA
[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
075
引用
收藏
页码：AB25 / AB25
页数：1
相关论文
共 50 条
  • [1] EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA, ACCORDING TO BASELINE BODY MASS INDEX: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Ambrose, C. S.
    Colice, G.
    Salapa, K.
    Parnes, J. R.
    Corren, J.
    THORAX, 2021, 76 : A83 - A83
  • [2] THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Corren, Jonathan
    Ambrose, Christopher
    Salapa, Kinga
    Parnes, Jane
    Colice, Gene
    CHEST, 2020, 158 (04) : 30A - 31A
  • [3] Tezepelumab Treatment Effect on Annualized Rate of Exacerbations by Baseline Biomarkers in Uncontrolled Severe Asthma Patients: Phase 2b PATHWAY Study
    Corren, J.
    Garcia Gil, E.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [4] The Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma According to Baseline Serum IL-5 and IL-13 Levels: Results from the Phase 2b PATHWAY Study
    Corren, J.
    Ambrose, C.
    Salapa, K.
    Parnes, J. R.
    Pham, T.
    Griffiths, J. M.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [5] Seasonal Variability of Exacerbations in Patients with Severe, Uncontrolled Asthma and Clinical Benefits of Tezepelumab: Results from the PATHWAY Phase 2b Study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [6] Seasonal variability of exacerbations in patients with severe, uncontrolled asthma and clinical benefits of tezepelumab: Results from the PATHWAY phase 2b study
    Corren, J.
    Karpefors, M.
    Hellqvist, A.
    Parnes, J. R.
    ALLERGY, 2020, 75 : 17 - 18
  • [7] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Karpefors, Martin
    Hellqvist, Asa
    Parnes, Jane R.
    Colice, Gene
    JOURNAL OF ASTHMA AND ALLERGY, 2021, 14 : 1 - 10
  • [8] Effects of Tezepelumab on Asthma Exacerbations and Type 2 Biomarkers in Patients with Severe, Uncontrolled Asthma with and Without Nasal Polyps: Results from a Post-Hoc Analysis of the Phase 2b PATHWAY Study
    Emson, C.
    Corren, J.
    Saapa, K.
    Hellqvist, A.
    Parnes, J. R.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [9] The Impact of Tezepelumab on Hospitalization and Emergency Department Visits in Patients with Severe Uncontrolled Asthma: Results from the Pathway Phase 2b Trial
    Corren, J.
    Chen, S.
    Callan, L.
    Garcia Gil, E.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [10] LONG-TERM EFFICACY OF TEZEPELUMAB IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA BY BASELINE BODY MASS INDEX
    Chupp, Geoffrey L.
    Lugogo, Njira L.
    Wechsler, Michael E.
    Lawson, Kaitlyn
    Lindsley, Andrew
    Spahn, Joe D.
    Ambrose, Christopher
    CHEST, 2023, 164 (04) : 9A - 14A
12345